Clinical trials: Dasatinib
Waldenstrom Macroglobulinemia, DASATINIB
Dasatinib In Waldenström Macroglobulinemia
This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations
- Trial name
- NCT04115059
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Jorge J. Castillo, MD
Carcinoma, Non-small Cell Lung
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
The purpose of this study is to establish whether patients with malignancy harboring a discoidin domain receptor 2 mutation or an inactivating B-RAF mutation will respond to dasatinib.
- Trial name
- NCT01514864
- Testing
- Dasatinib
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukaemia
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary.
- Trial name
- NCT05286528
- Testing
- Bosutinib, Imatinib, Nilotinib
- Where
- Hungary
- Volunteers
- 1,484 people
- Sponsor
- Pfizer
Non-Hodgkin's Lymphoma
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Primary Objective: To determine the maximum tolerated dose (MTD) of Dasatinib in relapsed or refractory non-hodgkin's lymphoma (NHL) patients and to determine the safety of Dasatinib in NHL.
- Trial name
- NCT00550615
- Testing
- Dasatinib, Dasatinib Maximum Tolerated Dose
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Nebraska
Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
This phase II trial studies how well dasatinib works in treating patients with ovarian, fallopian tube, endometrial, or peritoneal cancer that has come back or is persistent.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02059265
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 227 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or…
- Trial name
- NCT00700882
- Testing
- dasatinib
- Where
- 153 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eastern Cooperative Oncology Group
Chronic Phase Chronic Myeloid Leukemia
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying…
- Trial name
- DASCERN (NCT01593254)
- Testing
- Imatinib, Dasatinib
- Where
- 101 sites in United States, Argentina and 13 more
- Volunteers
- 262 people
- Sponsor
- Bristol-Myers Squibb
Leukemia
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
The primary objective of this study is to estimate the major cytogenetic response (MCyR) rate to Dasatinib in subjects with CP CML, complete and overall hematologic response (CHR and OHR) rate in subjects with AD CML or Ph+ ALL…
- Trial name
- NCT00529763
- Testing
- Dasatinib
- Where
- 14 sites in China
- Volunteers
- 121 people
- Sponsor
- Bristol-Myers Squibb
Multiple Indications Cancer
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.
- Trial name
- NCT02297139
- Testing
- Dasatinib
- Where
- 6 sites in France, Poland
- Volunteers
- 17 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia.
- Trial name
- NCT01256398
- Testing
- Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation
- Where
- 101 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
This is a single-arm, open-label, phase I/II study. In the phase I, patients with Human Epidermal Growth Factor Receptor 2 (HER2) positive MBC will be treated with paclitaxel, trastuzumab and increasing doses of dasatinib to…
- Trial name
- NCT01306942
- Testing
- Dasatinib, Trastuzumab, Paclitaxel
- Where
- 8 sites in Spain
- Volunteers
- 37 people
- Sponsor
- Spanish Breast Cancer Research Group
Alzheimer Disease
Senolytic Therapy to Modulate Progression of Alzheimer's Disease
The purpose of this pilot study is to evaluate whether a combination of two drugs, dasatinib (D) and quercetin (Q) [D+Q], penetrate the brain using cerebrospinal fluid (CSF) in older adults with early Alzheimer's disease (AD).
- Trial name
- SToMP-AD (NCT04063124)
- Testing
- Dasatinib + Quercetin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Leukemia, Myeloid, Chronic
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase…
- Trial name
- NCT02269267
- Testing
- Imatinib (Stopping their TKI), Dasatinib (Stopping their TKI), Nilotinib (Stopping their TKI)
- Where
- 16 sites in United States
- Volunteers
- 173 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the side effects and how well giving combination chemotherapy together with dasatinib works in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Trial name
- NCT01238211
- Testing
- Cytarabine, Dasatinib, Daunorubicin Hydrochloride
- Where
- 65 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Phase Chronic Myeloid Leukemia
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained…
- Trial name
- DASFREE (NCT01850004)
- Testing
- Dasatinib
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Glioma, High Grade Glioma
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR alterations, including newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG)…
- Conditions
- Glioma, High Grade Glioma, Pontine Tumors
- Trial name
- NCT03352427
- Testing
- Dasatinib, Everolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acute Lymphoblastic Leukemia
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
The primary objective of this study (TOTXVI) is to compare the clinical benefit, the pharmacokinetics, and the pharmacodynamics of polyethylene glycol-conjugated (PEG) asparaginase given in higher dose (HD PEG) versus those of…
- Trial name
- NCT00549848
- Testing
- Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT03023046
- Testing
- Cyclophosphamide, Dasatinib, Doxorubicin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Washington
Chronic Myeloid Leukemia, Chronic Phase
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
This is a Phase I/II single site, open label clinical trial. The purpose of the Phase I portion is to determine the safety, tolerability, and recommended Phase II dose of Eicosapentaenoic Acid (EPA) when given daily in…
- Trial name
- NCT04006847
- Testing
- Eicosapentaenoic Acid, Tyrosine kinase inhibitor
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Milton S. Hershey Medical Center
Breast Neoplasms, Triple Negative Breast Neoplasms
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Primary Objective: To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative…
- Trial name
- NCT02720185
- Testing
- Dasatinib, Conventional Surgery, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Wisconsin, Madison